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Abstract
Background: Hypertension is a prevalent chronic disease worldwide that remains poorly controlled. Recent studies
support the concept that the gut microbiota is involved in the development of hypertension and that dietary fibre
intake may act through the gut microbiota to lower blood pressure (BP). Resistant starch is a type of prebiotic fibre
which is metabolised by commensal bacteria in the colon to produce short-chain fatty acids (SCFAs), including
acetate, propionate, and butyrate. Previous work in pre-clinical models provides strong evidence that both prebiotic
fibre as well as SCFAs (i.e. postbiotics) can prevent the development of hypertension. The aim of this clinical trial is
to determine if acetylated and butyrylated modified resistant starch can decrease BP of hypertensive individuals via
the modulation of the gut microbiota and release of high levels of SCFAs.
Methods: This is a phase IIa double-blinded, randomised, cross-over, placebo controlled trial. Participants are
randomly allocated to receive either a diet containing 40 g/day of the modified resistant starch or placebo (corn
starch or regular flour) for 3 weeks on each diet, with a 3-week washout period between the two diets. BP is
measured in the office, at home, and using a 24-h ambulatory device. Arterial stiffness is measured using carotid-to-
femoral pulse wave velocity. Our primary endpoint is a reduction in ambulatory daytime systolic BP. Secondary
endpoints include changes to circulating cytokines, immune markers, and modulation to the gut microbiome.
Discussion: The findings of this study will provide the first evidence for the use of a combination of pre- and
postbiotics to lower BP in humans. The results are expected at the end of 2021.
Trial registration: Australia and New Zealand Clinical Trial Registry ACTRN12619000916145. Registered on 1 July
2019.
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Background
High blood pressure (BP), or hypertension, is a highly
prevalent chronic disease, affecting one in three people
worldwide [1]. Hypertension remains poorly controlled
due to low compliance and medication adherence [2, 3].
The pathogenesis of hypertension and BP control is
complex: combined with genetic and environmental fac-
tors, recent studies now support the concept that the
gut microbiota is involved in the development and main-
tenance of high BP [4]. Epidemiological studies suggest
that dietary components such as fibre may mitigate the
development of hypertension [5], and interventions to
increase fermentable and non-fermentable fibre intake
significantly reduced systolic and diastolic BP in patients
with hypertension [4, 6, 7].
Results from pre-clinical studies support resistant
starch is a type of dietary fibre that has potential to exert
different beneficial outcomes for cardiovascular disease
(CVD) [8], yet has been neglected in clinical trials. These
starches are considered prebiotic (i.e. substrates for
stimulating the growth of certain beneficial gut bacteria),
as they resist digestion in the upper gastrointestinal tract
and pass undigested to the large intestine, where they
are fermented by commensal bacteria. Diets rich in pre-
biotic fibre increase gut microbiota populations that
generate short-chain fatty acids (SCFAs), such as acetate,
propionate, and butyrate.
Earlier studies have found resistant starch intakes in
both Australia and the USA are low (approximately 3–9
g per person per day) [9, 10]. Resistant starches are het-
erogeneous in nature, and there are no current dietary
recommendations regarding intake. However, some have
suggested intake of 6 g per meal, or 20 g per day, will
promote health benefits, such modulation of post-
prandial glucose and insulin levels [9]. High amylose
maize starches (HAMS) are made up of approximately
50% resistant starch and are used in food products in
Australia (e.g. breads, cereals) and can also be purchased
as a standalone supplement [11]. Thus, there is a case
for a diet high in HAMS and, therefore, resistant starch
or prebiotic fibre to exert positive health effects to indi-
viduals and of interest, those with hypertension.
The relationship between diet, gut microbiome modula-
tion, and the availability of SCFAs is believed to be the key
to the ability of a high prebiotic fibre diet to ameliorate in-
flammatory diseases [12–14]. Early ex vivo studies showed
that acetate and butyrate mediate concentration-
dependent dilatation of ventral tail artery in rats and hu-
man colonic resistance arteries [15, 16]. These are consist-
ent with findings by us and others supporting that a diet
high in resistant starches [8] or direct supplementation
with acetate [8], propionate [17], and butyrate [18] prevent
the development of high BP and its cardio-renal complica-
tions in pre-clinical models. In pre-clinical models, lack of
resistant starches lead to the development of a hypertensi-
nogenic gut microbiota in germ-free mice [19]. Combined,
these studies suggest that the use of prebiotic resistant
starches and postbiotics (i.e. SCFAs) may lower BP, but
translational evidence in humans are lacking. Here, we de-
scribe our ongoing world-firstproof-of-concept phase IIa
clinical trial, the Microbial Interventions to Control and
Reduce Blood Pressure in Australia (MICRoBIA), where
we are assessing the use of an acetylated and butyrylated




It is hypothesised that the gut microbiota and their me-
tabolites acetate and butyrate prevent the development
of hypertension and that medicinal food containing pre-
biotic fibres and postbiotics (i.e. acetate and butyrate),
such as HAMSAB, can be used to lower BP. Thus, our
aim is to determine if HAMSAB, which produces high
levels of SCFAs as well as leading to the release of high
levels of acetate and butyrate as a result of microbial fer-
mentation could be used as a new strategy to lower BP.
Study design
This is a double-blinded, randomised, cross-over, pla-
cebo controlled trial as shown in Fig. 1.
Recruitment summary
Recruitment is being conducted through advertisement
placed around the Alfred Hospital (Melbourne, Australia)
precinct as well as public places (GP offices, shopping
malls/centres, noticeboards) in this locality. Previous re-
search participants who approved to be contacted for fu-
ture research were also contacted via email through a
large database to be considered for the trial. Online social
media platforms are also used to recruit participants
(Monash FODMAP platforms, Marques Lab, Facebook,
Twitter, Google ads). The trial gained exposure through
an article in a tabloid based in Melbourne (The Herald
Sun) as well as an article through a Monash University on-
line news platform (Monash Lens). Recruitment started in
July 2019 and is estimated to finish in October 2021.
Study population
Males and females with untreated hypertension as de-
fined by the Australian National Heart Foundation
guidelines [office BP ≥ 140/90 mmHg and 24 h ambula-
tory blood pressure monitoring (ABPM) ≥ 130/80)] are
being recruited for this study. Participants with masked
hypertension are included and defined as office BP ≤
140/90 mmHg but ABPM ≥ 130/80. Participants are also
required to have a BMI of 18.5–35 kg/m2, due to the as-
sociation between weight and the gut microbiota [20].
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Exclusion criteria include the use of anti-hypertensive
medication, office BP ≥ 165/100mmHg, recent use of
antibiotics (< 3months) or probiotics (< 6 weeks), type 1
or 2 diabetes, pregnancy, and the presence of gastro-
intestinal diseases. Participants are also excluded if there
are any dietary requirements (e.g. vegetarian and
coeliac). Figure 2 describes the current study population
at time of publication.
Sample size
In this proof-of-principle study, we estimate we will re-
quire 33 subjects to achieve 80% power with α = 0.05
(calculated effect size 0.5) to determine a 5 mmHg differ-
ence in ambulatory daytime systolic BP after intake of
modified HAMS for 3 weeks. The 3 weeks intervention
was chosen based on previously published papers [8, 19].
We will aim to recruit 38 participants per group to allow
for a 20% drop out rate. We have recruited 17 partici-
pants to date, with one dropout due to BP > 165/100
and requiring medication. One participant had to be ex-
cluded after completion of the trial due to antibiotic in-
take needed whilst in the second arm of the study,
resulting in 16 participants that have completed the trial.
Due to the SARS-COV-2 pandemic, we were forced to
stop the trial several times, which has caused several de-
lays in recruitment.
Trial status
We are currently recruiting participants.
Study protocol and measurements
A diagram of the study protocol (version 2, date 27 May
2019) is presented in Fig. 1. Participants are randomly
stratified based on age, sex and BMI using REDCap
(Version 9.1.0 Tennessee) to either a diet containing 40
Fig. 1 Design of our double-blind, cross-over, randomised trial. BP, blood pressure
Fig. 2 Recruitment summary. Out of 143 expressions of interest, 16
participants have finished the trial so far. BMI, body mass index; BP,
blood pressure
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g HAMSAB or placebo maize-starch daily by the study
coordinator. REDCap is also used to manage all the in-
formation by the study coordinator. The choice of use of
a placebo food instead of BP-lowering drug intervention
addresses the issue that participants who volunteered to
our study did not want to take medication in the first
place. Both the study participants and study coordinator
are blinded to the diet containing the prebiotic supple-
ment (thus, they are referred to Diet A and Diet B in the
Figures). The study period is 9 weeks: 3 weeks actively
on either diet, with a 3-week washout period in between.
The purpose of the washout period is to allow the gut
microbiota and levels of acetate and butyrate to return
to baseline. These will be confirmed in samples collected
in the third visit compared to the first visit. The washout
period was determined based on previous gut microbiota
studies with a similar design [21], based on the fact that
the gut microbiota can change rapidly (< 7 days) [22].
Since this is a cross-over study, data will be compared
between visits one and two, and visits three and four,
minimising the effect if we find that the effect of HAMS
AB lasted longer than 3 weeks in those randomised into
the intervention arm first. Participants are provided 2
meals daily and are instructed to eat their usual foods
around the trial’s food. The dietary intake of the partici-
pants is not restricted, and the foods provided to them
are suggested to in place of normal foods (i.e. replacing
a usual breakfast of toast with a ‘breakfast muffin’). To
increase compliance, we have opted to not replace every
meal. A sample 7-day meal plan that is cycled during the
3-week diet phase is shown in Table 1. Participants are
provided with a list of foods containing natural resistant
starches and SCFAs to avoid during the study period
(e.g. green banana flour, waxy maize starch, kombucha,
vinegars). Participants are provided with a food diary for
the duration of the study, where they document approxi-
mate intake in quartiles (i.e. 0, ¼, ½, ¾, all). This data is
then translated for nutritional analysis using FoodWorks
Professional Software (Version 7.01, Xyris, Queensland).
Participants are initially screened over the phone to as-
sess eligibility according to the inclusion and exclusion
criteria. Those that meet the inclusion criteria are in-
vited to attend a baseline assessment where signed con-
sent is obtained. At the baseline assessment, participants
spend approximately 60–90 min with the researcher for
all BP measurements, including testing of office BP,
carotid-to-femoral pulse wave velocity, as well as
providing the 24 h ABPM device and home monitoring
device. The researcher discusses the 3-day food diary
with the participants, collects the 24-h dietary recall, and
provides the faecal tubes with instructions for collection.
Primary outcome is a decrease in systolic BP. Office
BP is measured under resting conditions (> 5 min sit-
ting), with the researcher not in the room and an aver-
age of three measurements is taken using an automated
digital BP monitor (Omron Healthcare, Japan, HEM-
907). During the office baseline BP measurements, par-
ticipants are seated with their back supported, arms and
legs uncrossed, and not speaking. Participants are also
instructed on how to correctly measure their BP at home
according to the Australian Heart Foundation guidelines,
and they are provided with a calibrated and research ap-
proved BP monitor (Omron Healthcare, Japan, HEM-
7121) for the duration of the study for home BP mea-
surements. At home, participants take two readings at
the same time each day under rested conditions whilst
on either diet which they document in a BP diary. Par-
ticipants are also instructed to document any factors
that they believe may affect their BP in this diary (e.g.
medication changes, illnesses, severe stress).
Secondary outcome is a decrease in arterial stiffness.
Measurements of carotid-femoral pulse wave velocity
and pulse wave analysis are performed in duplicate using
the Sphygmocor XCEL device (AtCor Medical, Sydney,
NSW). Participants are seated and rested for the brachial
measurements of pulse wave analysis and in the supine
position for the pulse wave velocity measurement.
Mobil-O-Graph (I.E.M Industrielle Entwicklung Medi-
zintechnik GmbH) BP monitoring devices are used for
the 24 h ABPM measurements. This takes BP measure-
ments every 15 min during the day time and 30 min dur-
ing the night time period. Night and day time periods
are confirmed by a diary completed by the subject. Once
the ABPM monitor has been returned to the researcher
and hypertension has been confirmed, participants are
provided with study food. Participants receive letters
with their BP results which suggest when they should
follow-up with their medical team, according to the Na-
tional Heart Foundation of Australia BP guidelines.
Three-day food diaries and 24-h food recalls are used
to understand habitual dietary intake amongst the study
participants at each visit. Three-day food diaries are to
be completed over two week days and one weekend day.
This dietary information is recorded in FoodWorks
Table 1 Seven-day meal plan supplied for participants for 3 weeks
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Professional Software (Version 7.01, Xyris, Queensland)
to calculate the average energy and macronutrient intake
for each participant. Quantification of resistant starch is
calculated from the Monash University FODMAP data-
base and resistant starch report [23]. Participants are
also instructed to follow the Australian Government’s
‘Eat for Health’ guidelines on alcohol, which limits alco-
hol to no more than two standard drinks on any day,
and no more than four standard drinks on any occasion.
Participants also complete the Visual Analogue Scale
(VAS) questionnaire for gastrointestinal symptoms (e.g.
abdominal symptoms, pain, wind, nausea), and a daily
bowel symptom diary.
BMI and waist-to-hip ratio are measured at each visit.
Patients are instructed to not plan any intended weight
loss or weight gain strategies during the duration of the
study, due to the effect of weight changes on BP. Partici-
pants also record the amount and types of physical activ-
ity they have participated in, during the week prior to
each visit.
A fasting blood sample is taken on each visit and all
testing is performed at the site hospital (The Alfred Hos-
pital, Melbourne). Standard biochemical testing is per-
formed including fasting blood glucose and fasting lipids
and blood electrolytes and liver enzyme tests to deter-
mine renal and liver function (including eGFR, creatin-
ine, total protein, albumin, globulin, bilirubin, ALT,
GGT, ALP).
The third outcome is a change in levels of SCFAs.
Plasma and faecal SCFAs will be measured at the end of
the study using gas chromatography in triplicates, as
previously described [24]. Faecal DNA preserved in
DNA/RNA Shield and stored at – 80 °C will be ex-
tracted using the QIAamp PowerFecal DNA kit (Qia-
gen). The V4 region of the bacterial 16S rRNA will be
amplified by PCR using 20 ng of DNA, Platinum Hot
Start PCR master mix (ThermoFisher Scientific), 515F
and 926R primers (Bioneer), and methods previously de-
scribed [25] in a Veriti Thermal Cycler (ThermoFisher
Scientific). Two hundred and forty nanograms of the
product will be pooled, cleaned, and then sequenced in
an Illumina MiSeq sequencer (300 bp paired-end reads,
with minimum 100,000 reads per sample). 16S data will
be analysed using the QIIME2 workflow [26]. We will
analyse faecal samples collected from before, during (7
days) and after the interventions in terms of alpha diver-
sity (i.e. number of bacteria and distribution within sam-
ples), beta diversity (i.e. types of bacteria and prevalence
Fig. 3 Collection and analyses of the gut microbiome. Following measurement of blood pressure (office and 24 h ambulatory blood pressure
monitoring) and pulse wave velocity, participants collect a faecal sample. The DNA is then extracted; library targeting the 16S bacterial gene or
whole-metagenome is prepared and sequenced. Bioinformatics analyses are used to determine taxonomic differences (before/after placebo and
intervention), alpha diversity (i.e. within sample diversity), and beta diversity (i.e. between sample diversity). Plots are only representative
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between samples), and taxonomic changes according to
recent guidelines [27] (Fig. 3). This will inform further
metagenomics analyses.
The study coordinator and the principal investigators
meet weekly or fortnightly to monitor progress. Our
studied followed the SPIRIT reporting guidelines [28].
Adverse effects
Adverse effects would be reported to the Monash Uni-
versity Human Research Ethics Committee. Due to the
use of diet as our intervention, adverse events are un-
common. To this date, we have not experienced any ad-
verse events.
Data analysis
We will perform linear mixed model analyses for repeated
measures with between and within subjects to analyse the
phenotype such as BP and pulse wave velocity using SPSS
(version 25), where fixed effects include time (baseline,
after first arm, before second arm, after second arm) and
treatment group (placebo versus HAMSAB) [29, 30]. If
data is missing, we will use multiple imputation in SPSS.
Gut microbiome will be analysed using QIIME2 [26] and
other in-house bioinformatics pipelines (such as [19]).
Discussion
Research into the gut microbiome is evolving at a rapid
pace, and in recent years, causal links between the
microbiota and disease states, including hypertension,
have been discovered. Dietary manipulation via prebi-
otics increases microbial diversity and SCFA production,
which can infer benefits on the host. Translation of find-
ings from pre-clinical models into meaningful results in
human studies is important and has been achieved in
patients with type 2 diabetes [31]. In regard to hyperten-
sion, novel dietary strategies, such as the one described
in this trial, are essential, as the impact of cardiovascular
disease on the individual and public health systems are
immense. The findings from this study will provide the
first evidence for the use of a combination of pre- and
postbiotics to lower BP in humans.
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